In episode 442, James and Mike welcome back Mike Kolber to discuss all the evidence around biosimilars. The issue is exactly the same one we have had for decades with the question around brand name versus generic medications. Tune in and find out the answer. At the conclusion of this… Read More
In episode 441, James and Mike revisit the problem with guidelines. We talk about recent writings on the issues around guidelines. We discuss the main problems and believe it or not we give advice and suggestions for how to make them better. At the conclusion of this activity, participants will… Read More
In episode 440, Mike and James yet again invite Adrienne to go over all the evidence for treating toenail onychomycosis. We find that ~ 40% more people get better on oral treatments than on placebo. For topicals the number is closer to 10%. Topicals should likely only be used if… Read More
In episode 439, Mike and James invite Adrienne to take us through the impressively large amount of evidence for the PDE5 inhibitors for erectile dysfunction. We find that the NNTs are 2-3 for the not clearly defined endpoint of successful intercourse. There is a 20% absolute increase in adverse effects… Read More
In episode 438, Mike and James discuss 4 studies that likely could change what you are doing, or saying to your patients in your practice. Hip replacements – they last longer than you may think, Vitamin D – bigger isn’t better, actinic keratosis – 5-Flurouracil is best, and weight loss… Read More
